Neostigmine's role in Ogilvie syndrome treatment — the acetylcholinesterase inhibitor achieving over 80% efficacy in colonic decompression for acute colonic pseudo-obstruction (ACPO) — represents the most clinically validated pharmacological intervention, with the Ogilvie Syndrome Treatment Market reflecting neostigmine-driven pharmacological treatment as the dominant commercial...